



03-17-04

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Feige, et al.

Serial No.: 10/632,388

Group Art Unit No.: 1642

Filed: July 31, 2003

Examiner: S. Huff

For: MODIFIED PEPTIDES AS THERAPEUTIC AGENTS

Docket No.: A-527C

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Under the guidelines of 37 C.F.R. 1.97, applicants submit a copy of each of the references listed on the attached supplemental PTO-1449 form for consideration by the Examiner and provides a copy of each of the listed references for consideration by the Examiner.

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, or before the mailing of a first Office action after the filing of a request for continued examination under section 1.114, whichever event occurs last. 37 CFR 1.97(b).

Applicants request consideration of this information and passage of the application to issue.

The Commissioner is hereby authorized to charge any additional fees which may be required or credit any overpayment to Deposit Account No. 01-0519 in the name of Amgen Inc. An original and one copy of this paper are enclosed.

Respectfully submitted,

Timothy J. Gaul

Attorney for Applicants

Registration No.: 33,111

Phone: (805) 447-2688

Date: March 15, 2004

Please send all future correspondence to:
U.S. Patent Operations/[TJG]
Dept. 4300, M/S 27-4-A
AMGEN INC.
One Amgen Center Drive
Thousand Oaks, California 91320-1799

EXPRESS MAIL CERTIFICATE

"Express Mail" label number: EV352488825US

Date of Deposit: March 15, 2004

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Sherry St. Andrew

Printed Name

Signature

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Modified Form PTO-1449 LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	Atty. Docket ...	Serial No.
	A-527C	10/632.388
	Applicant Feige et al	
	Filing Date July 31, 2003	Group 1642

EXAMINER'S INITIALS

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

C113	Abuchowski et al. (1981), "Soluble Polymer - Enzyme Adducts," <i>Enzymes as Drugs</i> : Chapter 13, Hoenberg and Roberts, eds., Wiley-Interscience, New York, NY, pp. 367-383.
C114	Adjei et al. (1990), "Pulmonary Delivery of Peptide Drugs: Effect of Particle Size on Bioavailability of Leuprolide Acetate in Healthy Male Volunteers," <i>Pharmaceutical Research</i> 7:565-569.
C115	Adjei et al. (1990), "Bioavailability of leuprolide following intratracheal administration to beagle dogs," <i>International Journal of Pharmaceutics</i> 61:135-144.
C116	Alexander et al. (1996), "Deficiencies in Progenitor Cells of Multiple Hematopoietic Lineages and Defective Megakaryocytopoiesis in Mice Lacking the Thrombopoietin Receptor c-Mpl," <i>Blood</i> 87:2162-2170.
C117	Bartley et al. (1994), "Identification and Cloning of a Megakaryocyte Growth and Development Factor That is a Ligand for the Cytokine Receptor Mpl," <i>Cell</i> 77:1117-1124.
C118	Basser et al. (1996), "Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer," <i>The Lancet</i> 348:1279-1281.
C119	Braquet et al. (1989), "Effect of Endothelin-1 on Blood Pressure and Bronchopulmonary System of the Guinea Pig," <i>Journal of Cardiovascular Pharmacology</i> , 13 (Suppl.5):S143-S146.
C120	Carosella et al. (1990), "Anti-Human Interleukin 2 Receptor Monoclonal Antibody Isotypic Switching: Chimeric Rat-Human Antibodies," <i>Human Immunology</i> 29:233-246.
C121	Chang et al. (1995), "Cloning and Characterization of the Human Megakaryocyte Growth and Development Factor (MGDF) Gene," <i>The Journal of Biological Chemistry</i> 270:511-514.
C122	Choi et al. (1995), "Platelets Generated In Vitro From Proplatelet-Displaying Human Megakaryocytes are Functional," <i>Blood</i> 85:402-413.
C123	Clackson et al. (1995), "A Hot Spot of Binding Energy in a Hormone-Receptor Interface," <i>Science</i> 267:383-386.
C124	Creighton, Thomas E., <i>Proteins: Structures and Molecular Principles</i> , W.H. Freeman and Company, New York, pp. 70-86 (1983)
C125	Davis et al. (1985), "Preparation and Characterization of Antibodies with Specificity for the Amino-Terminal Tetrapeptide Sequence of the Platelet-Derived Connective Tissue," <i>Biochemistry International</i> 10:395-404.
C126	Debili et al., (1995) "The Mpl Receptor is Expressed in the Megakaryocytic Lineage From Late Progenitors to Platelets," <i>Blood</i> 85:391-401.
C127	Debs et al. (1988), "Lung-Specific Delivery of Cytokines Induces Sustained Pulmonary and Systemic Immunomodulation in Rats," <i>The Journal of Immunology</i> 140:3482-3488.
C128	de Sauvage et al. (1994), "Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand," <i>Nature</i> 369:533-538.


EXAMINER:

Date Considered:

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Modified Form PTO-1449 LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	Atty. Docket No.	A-527C	Serial No.	10/632.388
	Applicant			
	Feige et al			
	Filing Date	July 31, 2003	Group	1642

EXAMINER'S INITIALS

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)


C129	Ellison et al. (1982), "The nucleotide sequence of a human immunoglobulin C _{γ1} gene," <i>Nucleic Acids Research</i> 10:4071-4079.
C130	Erickson et al., <i>The Proteins</i> , 3 rd ed., 2: Chapter 3, Solid-Phase Peptide Synthesis, Neurath et al., eds., Academic Press, New York, pp. 255-527 (1976)
C131	Finn et al., <i>The Proteins</i> , 3 rd ed., 2: Chapter 2, Solid-Phase Peptide Synthesis, Neurath et al., eds., Academic Press, New York, pp. 105-253 (1976)
C132	Fisher et al. (1996), "Treatment of Septic Shock With the Tumor Necrosis Factor Receptor:Fc Fusion Protein," <i>The New England Journal of Medicine</i> 334:1697-1702.
C133	Gurney et al. (1995), "Genomic Structure, Chromosomal Localization, and Conserved Alternative Splice Forms of Thrombopoietin," <i>Blood</i> 85:981-988.
C134	Hokom et al. (1995), "Pegylated Megakaryocyte Growth and Development Factor Abrogates the Lethal Thrombocytopenia Associated With Carboplatin and Irradiation in Mice," <i>Blood</i> 86:4486-4492.
C135	Hubbard et al. (1989), "Anti-Neutrophil-Elastase Defenses of the Lower Respiratory Tract in α1-Antitrypsin Deficiency Directly Augmented with an Aerosol of α1-Antitrypsin," <i>Annals of Internal Medicine</i> 111:206-212.
C136	Kato et al. (1995), "Purification and Characterization of Thrombopoietin," <i>Journal of Biochemistry</i> 118:229-236.
C137	Kaushansky et al. (1994), "Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin," <i>Nature</i> 369:568-571.
C138	Kimura et al. (1999), "Peptide Mimetic of Thrombopoietin Stimulates Differentiation in Mouse Bone Marrow Cells," <i>Journal of Biochemistry, Molecular Biology & Biophysics</i> 2:281-286.
C139	Kuter et al. (1994), "The purification of megapoeitin: A physiological regulator of megakaryocyte growth and platelet production," <i>Proceedings from the National Academy of Sciences USA</i> 91:11104-11108.
C140	[DUPLICATE OF C137] Kaushansky et al. (1994), "Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo," <i>Nature</i> 369:565-568.
C141	Love et al. (1989), "Recombinant Antibodies Possessing Novel Effector Functions," <i>Methods in Enzymology</i> 178:515-527.
C142	Marshall, Keith, <i>Modern Pharmaceutics</i> , Chapter 10: Solid Oral Dosage Forms, G.S. Banker and C.T. Rhodes eds., School of Pharmacy, University of Bradford, Bradford, Yorkshire, England, pp. 359-427 (1979)
C143	Merrifield, R.B. (1963), "Solid Phase Peptide Synthesis," <i>Journal of the American Chemical Society</i> 85:2149-2154.
C144	Methia et al. (1993), "Oligodeoxynucleotides Antisense to the Proto-oncogene c-mpl Specifically Inhibit In Vitro Megakaryocytopoiesis," <i>Blood</i> 82:1395-1401.

EXAMINER:	Date Considered:
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Modified Form PTO-1449 LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	Atty. Docket ... A-527C	Serial No. 10/632,388
	Applicant Feige et al	
	Filing Date July 31, 2003	Group 1642

EXAMINER'S
INITIALS**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

C145	Palacios et al. (1985), "IL3-Dependent Mouse Clones That Express B-220 Surface Antigen, Contain Ig Genes in Germ-Line Configuration, and Generates B Lymphocytes In Vivo," <i>Cell</i> 41:727-734.
C146	Rasko et al. (1997), "Mpl Ligand (MGDF) Alone and in Combination with Stem Cell Factor (SCF) Promotes Proliferation and Survival of Human Megakaryocyte, Erythroid and Granulocyte/Macrophage Progenitors," <i>Stem Cells</i> 15:33-42.
C147	Ravin et al., Remington Pharmaceutical Sciences, 18 th ed., Chapter 75: Preformulation, pp. 1435-1712 (1990)
C148	Roberts et al. (1997), "RNA-peptide fusions for the in vitro selection of peptides and proteins," <i>Proceedings from the National Academy of Sciences USA</i> 94:12297-12302.
C149	Sheridan et al. (1997), "Biology of thrombopoiesis and the role of Mpl ligand in the production and function of platelets," <i>Platelets</i> 8:319-332.
C150	Smith et al. (1989), "Pulmonary Deposition and Clearance of Aerosolized Alpha-1 Proteinase Inhibitor Administered to Dogs and to Sheep," <i>Journal of Clinical Investigation</i> 84:1145-1154.
C151	Stewart et al., Solid Phase Peptide Synthesis: Table of Contents and Indexes only, W.H. Freeman and Company, San Francisco (1969)
C152	Syed et al. (1998), "Efficiency of signaling through cytokine receptors depends critically on receptor orientation," <i>Nature</i> 395:511-516.
C153	Tai et al. (1990), "A Bifunctional Fusion Protein Containing Fc-Binding Fragment B of Staphylococcal Protein A Amino Terminal to Antidigoxin Single-Chain Fv," <i>Biochemistry</i> 29:8024-8030.
C154	Ulich et al. (1995), "Megakaryocyte Growth and Development Factor Ameliorates Carboplatin-Induced thrombocytopenia in Mice," <i>Blood</i> 86: 971-976.
C155	Vignon et al. (1992), "Molecular cloning and characterization of MPL, the human homolog of the v-mpl oncogene: Identification of a member of the metapoeitic growth factor receptor superfamily," <i>Proceedings from the National Academy of Sciences USA</i> 89:5640-5644.
C156	Wells et al. (1996), "Hematopoietic Receptor Complexes," <i>Annual Review of Biochemistry</i> 65:609-634.
C157	Wrighton et al. (1996), "Increased Potency of an Erythropoietin Peptide Mimetic Through Covalent Dimerization," <i>Nature Biotech.</i> 15:1261-1265.
C158	Wrighton et al. (1996), "Small Peptides as Potent Mimetics of the Protein Hormone Erythropoietin," <i>Science</i> 273:458-463.
C159	Zeigler et al. (1994), "In Vitro Megakaryocytopoietic and Thrombopoietic Activity of c-mpl Ligand (TPO) on Purified Murine Hematopoietic Stem Cells," <i>Blood</i> 84:4045-4052.

EXAMINER:	Date Considered:
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	